Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between δ-aminolevulinic acid–induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters

Clinical article

Restricted access

Object

The aim of this study was to investigate the relationships between intraoperative fluorescence, features on MR imaging, and neuropathological parameters in 11 cases of newly diagnosed glioblastoma multiforme (GBM) treated using protoporphyrin IX (PpIX) fluorescence-guided resection.

Methods

In 11 patients with a newly diagnosed GBM, δ-aminolevulinic acid (ALA) was administered to enhance endogenous synthesis of the fluorophore PpIX. The patients then underwent fluorescence-guided resection, coregistered with conventional neuronavigational image guidance. Biopsy specimens were collected at different times during surgery and assigned a fluorescence level of 0–3 (0, no fluorescence; 1, low fluorescence; 2, moderate fluorescence; or 3, high fluorescence). Contrast enhancement on MR imaging was quantified using two image metrics: 1) Gd-enhanced signal intensity (GdE) on T1-weighted subtraction MR image volumes, and 2) normalized contrast ratios (nCRs) in T1-weighted, postGd-injection MR image volumes for each biopsy specimen, using the biopsy-specific image-space coordinate transformation provided by the navigation system. Subsequently, each GdE and nCR value was grouped into one of two fluorescence categories, defined by its corresponding biopsy specimen fluorescence assessment as negative fluorescence (fluorescence level 0) or positive fluorescence (fluorescence level 1, 2, or 3). A single neuropathologist analyzed the H & E–stained tissue slides of each biopsy specimen and measured three neuropathological parameters: 1) histopathological score (0–IV); 2) tumor burden score (0–III); and 3) necrotic burden score (0–III).

Results

Mixed-model analyses with random effects for individuals show a highly statistically significant difference between fluorescing and nonfluorescing tissue in GdE (mean difference 8.33, p = 0.018) and nCRs (mean difference 5.15, p < 0.001). An analysis of association demonstrated a significant relationship between the levels of intraoperative fluorescence and histopathological score (χ2 = 58.8, p < 0.001), between fluorescence levels and tumor burden (χ2 = 42.7, p < 0.001), and between fluorescence levels and necrotic burden (χ2 = 30.9, p < 0.001). The corresponding Spearman rank correlation coefficients were 0.51 (p < 0.001) for fluorescence and histopathological score, and 0.49 (p < 0.001) for fluorescence and tumor burden, suggesting a strongly positive relationship for each of these variables.

Conclusions

These results demonstrate a significant relationship between contrast enhancement on preoperative MR imaging and observable intraoperative PpIX fluorescence. The finding that preoperative MR image signatures are predictive of intraoperative PpIX fluorescence is of practical importance for identifying candidates for the procedure. Furthermore, this study provides evidence that a strong relationship exists between tumor aggressiveness and the degree of tissue fluorescence that is observable intraoperatively, and that observable fluorescence has an excellent positive predictive value but a low negative predictive value.

Abbreviations used in this paper: ALA = δ-aminolevulinic acid; ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; FGR = fluorescence-guided resection; GBM = glioblastoma multiforme; GdE = Gd-enhanced signal intensity; nCR = normalized contrast ratio; NPV = negative predictive value; PpIX = protoporphyrin IX; PPV = positive predictive value; ROI = region of interest.

Article Information

Address correspondence to: David W. Roberts, M.D., Section of Neurosurgery, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, New Hampshire 03756. email: David.W.Roberts@dartmouth.edu.

Please include this information when citing this paper: published online April 9, 2010; DOI: 10.3171/.2010.2.JNS091322.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    Case 3. Images of a right parietal lesion. A: During resection, the surgical cavity displayed a high level of PpIX fluorescence (red) at the focal point of the surgical microscope (white cross hairs). B–D: Navigational information localized the focal point to an area of high contrast enhancement (red asterisks on MR images). E: Later during resection, the focal point of the operating microscope (white cross hairs) is focused on tissue with no observable PpIX fluorescence. F–H: Navigational information localized the focal point to an area without contrast enhancement (red asterisks).

  • View in gallery

    Diagrams of the 95% CIs of the mean of MR image measures. Left: The 95% CIs of the mean for the GdE values from subtraction images of both fluorescent ([(+) F]; 57 samples, mean 15.38, 95% CI 11.07–19.69) and nonfluorescent ([(–) F]; mean 7.54, 95% CI 2.14–12.94) groups (random-effects, mixed model: mean difference 8.33, 95% CI 1.42–15.24; p = 0.018). Right: The 95% CIs of the mean for the nCR of both fluorescent (77 samples, mean 1.10, 95% CI –0.49 to 2.69) and nonfluorescent (mean –3.99, 95% CI –5.67 to –2.32) groups (random-effects, mixed model: mean difference 5.15, 95% CI 2.54–7.77; p < 0.001). The small black square in the middle of the vertical line represents the mean, and the whiskers represent the upper and lower 95% confidence limits of the mean.

  • View in gallery

    Percentage bar graphs of fluorescence and neuropathological parameters. A relationship between qualitative fluorescence levels (0–3) and the two neuropathological parameters was observed. The Spearman rank correlation was 0.51 (p < 0.001) for the correlation between fluorescence and histopathological score (left), and 0.49 (p < 0.001) for the correlation between fluorescence and tumor burden (right).

References

  • 1

    Albert FKForsting MSartor KAdams HPKunze S: Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34:45611994

  • 2

    Barker FG IIPrados MDChang SMGutin PHLamborn KRLarson DA: Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg 84:4424481996

  • 3

    Bogaards AVarma ACollens SPLin AGiles AYang VX: Increased brain tumor resection using fluorescence image guidance in a preclinical model. Lasers Surg Med 35:1811902004

  • 4

    Collaud SJuzeniene AMoan JLange N: On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation. Curr Med Chem Anticancer Agents 4:3013162004

  • 5

    Eljamel MSGoodman CMoseley H: ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial. Lasers Med Sci 23:3613672008

  • 6

    Fitzmaurice GMLaird NMWare JH: Applied Longitudinal Analysis Hoboken, NJJohn Wiley & Sons2004

  • 7

    Friesen SAHjortland GOMadsen SJHirschberg HEngebraten ONesland JM: 5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review). Int J Oncol 21:5775822002

  • 8

    Hefti Mvon Campe GMoschopulos MSiegner ALooser HLandolt H: 5-aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery: a one-year experience at a single institutuion. Swiss Med Wkly 138:1801852008

  • 9

    Ishihara RKatayama YWatanabe TYoshino AFukushima TSakatani K: Quantitative spectroscopic analysis of 5-aminolevulinic acid-induced protoporphyrin IX fluorescence intensity in diffusely infiltrating astrocytomas. Neurol Med Chir (Tokyo) 47:53572007

  • 10

    Kajimoto YKuroiwa TMiyatake SIchioka TMiyashita MTanaka H: Use of 5-aminolevulinic acid in fluorescence-guided resection of meningioma with high risk of recurrence. Case report. J Neurosurg 106:107010742007

  • 11

    Kennedy JCMarcus SLPottier RH: Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. J Clin Laser Med Surg 14:2893041996

  • 12

    Koc KAnik ICabuk BCeylan S: Fluorescein sodium-guided surgery in glioblastoma multiforme: a prospective evaluation. Br J Neurosurg 22:991032008

  • 13

    Kremer PMahmoudreza FDing RPritsch MZoubaa SFrei E: Intraoperative fluorescence staining of malignant brain tumors using 5-aminofluorescein-labeled albumin. Neurosurgery 64:3 Suppl53612009

  • 14

    Kuroiwa TKajimoto YOhta T: Comparison between operative findings on malignant glioma by a fluorescein surgical microscopy and histological findings. Neurol Res 21:1301341999

  • 15

    Kuroiwa TKajimoto YOhta T: Development of a fluorescein operative microscope for use during malignant glioma surgery: a technical note and preliminary report. Surg Neurol 50:41491998

  • 16

    Kuroiwa TKajimoto YOhta T: Surgical management for supratentorial astrocytic tumors. Minim Invasive Neurosurg 42:1821861999

  • 17

    Lacroix MAbi-Said DFourney DRGokaslan ZLShi WDeMonte F: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:1901982001

  • 18

    Louis DNOhgaki HWiestler ODCavenee WKBurger PCJouvet A: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:971092007

  • 19

    Miyatake SKuroiwa TKajimoto YMiyashita MTanaka HTsuji M: Fluorescence of non-neoplastic, magnetic resonance imaging-enhancing tissue by 5-aminolevulinic acid: case report. Neurosurgery 61:E1101E11042007

  • 20

    Moore GEPeyton WTFrench LAWalker WW: The clinical use of fluorescein in neurosurgery: the localization of brain tumors. J Neurosurg 5:3923981948

  • 21

    Morofuji YMatsuo THayashi YSuyama KNagata I: Usefulness of intraoperative photodynamic diagnosis using 5-aminolevulinic acid for meningiomas with cranial invasion: technical case report. Neurosurgery 62:3 Suppl 11021042008

  • 22

    Murray KJ: Improved surgical resection of human brain tumors: Part I. A preliminary study. Surg Neurol 17:3163191982

  • 23

    Okuda TKataoka KTaneda M: Metastatic brain tumor surgery using fluorescein sodium: technical note. Minim Invasive Neurosurg 50:3823842007

  • 24

    Pichlmeier UBink ASchackert GStummer W: Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 10:102510342008

  • 25

    Pijl MEDoornbos JWasser MNvan Houwelingen HCTollenaar RABloem JL: Quantitative analysis of focal masses at MR imaging: a plea for standardization. Radiology 231:7377442004

  • 26

    Shinoda JYano HYoshimura SOkumura AKaku YIwama T: Fluorescence-guided resection of glioblastoma multi-forme by using high-dose fluorescein sodium. Technical note. J Neurosurg 99:5976032003

  • 27

    Stepp HBeck TPongratz TMeinel TKreth FWTonn JCh: ALA and malignant glioma: fluorescence-guided resection and photodynamic treatment. J Environ Pathol Toxicol Oncol 26:1571642007

  • 28

    Stummer WNovotny AStepp HGoetz CBise KReulen HJ: Fluorescence-guided resection of glioblastoma multi-forme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93:100310132000

  • 29

    Stummer WPichlmeier UMeinel TWiestler ODZanella FReulen HJ: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:3924012006

  • 30

    Stummer WReulen HJMeinel TPichlmeier USchumacher WTonn JC: Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:5645762008

  • 31

    Stummer WReulen HJNovotny AStepp HTonn JC: Fluorescence-guided resections of malignant gliomas—an overview. Acta Neurochir Suppl 88:9122003

  • 32

    Stummer WStepp HMöller GEhrhardt ALeonhard MReulen HJ: Technical principles for protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue. Acta Neurochir (Wien) 140:99510001998

  • 33

    Stummer WStocker SWagner SStepp HFritsch CGoetz C: Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 42:5185261998

  • 34

    Sun HRoberts DWFarid HWu ZHartov APaulsen KD: Cortical surface tracking using a stereoscopic operating microscope. Neurosurgery 56:1 Suppl86972005

  • 35

    Utsuki SMiyoshi NOka HMiyajima YShimizu SSuzuki S: Fluorescence-guided resection of metastatic brain tumors using a 5-aminolevulinic acid-induced protoporphyrin IX: pathological study. Brain Tumor Pathol 24:53552007

  • 36

    Utsuki SOka HMiyajima YShimizu SSuzuki SFujii K: Auditory alert system for fluorescence-guided resection of gliomas. Neurol Med Chir (Tokyo) 48:95982008

  • 37

    Utsuki SOka HSato SShimizu SSuzuki STanizaki Y: Histological examination of false positive tissue resection using 5-aminolevulinic acid-induced fluorescence guidance. Neurol Med Chir (Tokyo) 47:2102142007

  • 38

    Utsuki SOka HSato SSuzuki SShimizu STanaka S: Possibility of using laser spectroscopy for the intraoperative detection of nonfluorescing brain tumors and the boundaries of brain tumor infiltrates. Technical note. J Neurosurg 104:6186202006

  • 39

    Valdés PAFan XJi SHarris BTPaulsen KDRoberts DW: Estimation of brain deformation for volumetric image updating in protoporphyrin IX fluorescence-guided resection. Stereotact Funct Neurosurg 88:1102010

  • 40

    Yang VXMuller PJHerman PWilson BC: A multispectral fluorescence imaging system: design and initial clinical tests in intra-operative Photofrin-photodynamic therapy of brain tumors. Lasers Surg Med 32:2242322003

TrendMD

Cited By

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 167 167 20
Full Text Views 143 143 0
PDF Downloads 70 70 1
EPUB Downloads 0 0 0

PubMed

Google Scholar